None of the FcγR polymorphisms were found to be significantly associated with PFS or overall survival (OS), but patients homozygous for the high affinity binding alleles who received conatumumab in combination with paclitaxel and carboplatin for NSCLC had a trend toward longer OS [125]. The gene discussed is FCGR2A; the disease is non-small cell lung carcinoma.